Second Addendum to Commission A13-44 (Ipilimumab, New Therapeutic Indication) [Internet].

On 7 May 2014 the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a supplementary assessment for Commission A13-44 (benefit assessment of ipilimumab, new therapeutic indication) and for Commission A14-11 (Addendum to Commission A13-44 [ipilimumab, new therapeutic indication]).

http://ift.tt/2ruYywh